Elahere, which won initial U.S. Food and Drug Administration approval in 2022 for platinum-resistant ovarian cancer, was the key asset in AbbVie's $10.1 billion acquisition of biotech ImmunoGen that ...

That candidate hits the same target as Elahere, the ADC that AbbVie acquired in its $10 billion takeover of ImmunoGen. Elahere received full FDA approval in ovarian cancer this year, but ...

Even more alarming is AbbVie's payout ratio of 216.7%, far surpassing the peer average of 141%. This sky-high figure means ...

And as targeting technology improves, large pharma companies are paying closer attention to the drug field and the many smaller biotechnology firms within ... chemistry and biomarker technology to ...

Image Source: Getty Images ... This yield slightly exceeds the average of 3.12% among its big pharma and blue-chip biotech peers. The company's five-year dividend growth rate of 6.1% compares ...

CG Oncology remains the biggest IPO winner this year, having raised $380m in January. Image credit: Shutterstock / JHVEPhoto. Bicara Therapeutics has raised $362m in gross proceeds from its initial ...

TOI.in Representative image. Bharat Biotech on Wednesday announced a collaboration with Alopexx, Inc. for the co-development and commercialisation of the latter's proprietary broad-spectrum ...

Manuel Balce Ceneta - staff, ASSOCIATED PRESS Sep 12, 2024 16 mins ago 0 ...

Jose Luis Magana - freelancer, ASSOCIATED PRESS Sep 12, 2024 Sep 12, 2024 0 ...

Amgen today announced the presentation of new data showcasing IMDELLTRATM (tarlatamab-dlle), a first-in-class delta-like ligand 3 (DLL3)-targeting Bispecific T-cell Engager (BiTE®) molecule, at ...

Manuel Balce Ceneta - staff, ASSOCIATED PRESS Sep 12, 2024 Sep 12, 2024 0 ...